Browse the evidence

Dual incretin agonists (GLP-1/GIP) and triple agonists (GLP-1/GIP/Glucagon) show superior efficacy in reducing liver fat, inflammation, and fibrosis compared to GLP-1 mono-agonists in animal models, suggesting potential for enhanced clinical outcomes in MASLD.

Research suggests that newer 'dual' (GLP-1/GIP) and 'triple' (GLP-1/GIP/Glucagon) agonists may offer even greater benefits for liver health than current GLP-1 drugs, particularly in reducing liver fat and inflammation. These are still largely in clinical trials or early adoption phases for liver disease. If standard GLP-1 therapy is insufficient, discuss these newer multi-agonist options with your hepatologist or endocrinologist, keeping in mind that long-term human data for liver-specific outcomes is still being gathered.

Engineered bacteria (SYNB1020) that overproduce arginine to convert gut ammonia into L-arginine successfully lower systemic ammonia and improve survival in animal models of liver failure, but failed to show efficacy in a Phase Ib/IIa clinical trial for cirrhosis patients.

While engineered bacteria show promise in animals for clearing liver toxins, current clinical trials for liver disease patients have not yet succeeded. Do not expect this specific therapy to be available or effective for cirrhosis at this time.

Engineered bacteria producing GLP-1 or butyrate can improve glucose tolerance, insulin sensitivity, and reduce body weight in animal models of obesity and diabetes.

Research shows that engineered gut bacteria can produce hormones like GLP-1 or butyrate to improve metabolism in animals. This is a promising area for future oral treatments for diabetes and obesity, but it is not yet a standard therapy.

Dietary restriction (DR), including caloric restriction (CR) and intermittent fasting (IF), delays aging and extends healthspan by regulating nutrient-sensing pathways and gut microbiota.

To leverage dietary restriction for anti-aging, you don't necessarily need to cut calories drastically all day. Consider Time-Restricted Eating (eating within a 4-12 hour window) or Intermittent Fasting patterns like the 5:2 diet. These methods regulate nutrient-sensing pathways and gut microbiota similarly to strict calorie counting but are easier to sustain long-term. Focus on consistency and moderate restriction (10-30% if doing CR) to avoid negative side effects like muscle loss.

Activation of Gq-coupled receptors in brown and beige adipocytes generally suppresses thermogenic competence, whereas specific Gq receptors (like GPR120) can boost lipid oxidation and mitochondrial respiration.

The role of Gq receptors in fat burning is complex. While some Gq receptors (like those activated by acetate) may reduce fat-burning capacity, others (like GPR120, activated by fatty acids) can boost it. This complexity makes it a challenging target for simple drug development.

GLP-1 RAs show therapeutic potential in neurological disorders, including Alzheimer's and Parkinson's disease, by reducing amyloid-β/tau pathology, neuroinflammation, and promoting neuronal survival.

GLP-1 medications are being studied for Alzheimer's and Parkinson's disease. Some trials show promise in slowing brain volume loss, but results are mixed. They are not yet a standard treatment for these conditions. Consult a neurologist if interested in clinical trials.

GLP-1 receptor activation in the brain reduces the reward value of food, suggesting potential therapeutic applications for treating addiction to food and substances of abuse.

Research suggests that GLP-1 medications might help treat addiction by changing how your brain rewards food or substances. If you struggle with addictive behaviors, this emerging area of science offers hope for treatments that target the brain's reward system directly.

None of the combined antidiabetic therapies (DPP4i, GLP1RA, TZD, SGLT2i) showed a significant change in blood pressure compared to metformin alone in women with PCOS.

Do not expect adding DPP4 inhibitors, GLP1RAs, TZDs, or SGLT2 inhibitors to metformin to significantly lower your blood pressure. Focus on these combinations for glycemic, lipid, or weight management instead.

GLP-1 receptor agonists (GLP-1RAs) are associated with an emerging signal of suicidality, including suicidal ideation, attempts, and completed suicide, based on pharmacovigilance data, though large randomized controlled trials have not demonstrated a statistically significant causal increase in risk.

GLP-1 medications (like Ozempic or Wegovy) have been linked to reports of suicidal thoughts in pharmacovigilance databases, creating a safety signal. However, large clinical trials involving thousands of patients have not found a statistically significant increase in psychiatric events compared to placebo. The absolute risk appears to be very low. Clinicians should monitor patients, especially those with a history of mental health conditions, but the proven benefits for weight loss and heart health generally outweigh this rare risk for most users.

Combining HMB (3g/day) with Resistance Training does not provide a statistically significant additional benefit to muscle mass or strength compared to Resistance Training alone in elderly sarcopenic patients after hip surgery.

You do not need to take HMB if you are doing Resistance Training after hip surgery. RT alone is enough to build muscle and strength; adding HMB does not provide extra benefit for these metrics.

Low glycaemic index (GI) or low glycaemic load (GL) diets do not result in greater weight loss or improved metabolic markers compared to higher GI/GL diets or other standard diets in people with overweight or obesity.

If you are trying to lose weight, switching to a low GI or GL diet is unlikely to give you better results than other diets. Focus on creating a sustainable energy deficit rather than prioritizing the glycaemic index of foods.

Genotype-matched dietary interventions (low-fat vs. low-carbohydrate) may not consistently predict weight loss success in postmenopausal women compared to general overweight populations.

Do not rely solely on genetic testing to dictate whether you should eat low-fat or low-carb. Focus on sustainable dietary patterns like DASH or MED, as genotype matching has not consistently proven superior for weight loss in recent large studies.

Chronic consumption of monosodium glutamate (MSG) is associated with increased risk of obesity and weight gain, primarily through mechanisms involving hypothalamic damage, leptin resistance, and altered gut microbiota.

While MSG is legally safe, emerging research suggests high chronic intake, especially from processed foods with hidden MSG, may disrupt appetite regulation and contribute to weight gain. To mitigate potential risk, prioritize whole foods and check labels for hidden sources like hydrolyzed protein or yeast extract.

Long-acting GLP-1 receptor agonists (GLP-1RAs) attenuate obesity and reverse leptin resistance by reshaping gut microbiota to increase Akkermansia muciniphila, which produces inosine to activate the macrophage A2A pathway, thereby reducing adipocyte leptin levels.

This research suggests that GLP-1 medications (like semaglutide or liraglutide) may work partly by changing your gut bacteria to produce a molecule called inosine. This molecule helps reduce leptin, a hormone that regulates fat storage. While you cannot directly control this pathway, maintaining gut health through diet may support the effectiveness of these medications.

Specific additives found in UPFs, such as carrageenan and endocrine-disrupting chemicals like Bisphenol-A (BPA) and acrylamide, contribute to T2DM risk through mechanisms involving insulin resistance, inflammation, and gut microbiota alteration.

Be aware that certain additives (carrageenan, specific emulsifiers) and packaging-derived chemicals (BPA, phthalates) in UPFs may promote insulin resistance and inflammation. Reducing intake of products containing these specific ingredients, especially sugary beverages and processed meats, may lower T2DM risk.

Tirzepatide may allow some patients with moderate OSA (AHI 15-30) who are asymptomatic (except for snoring) to discontinue CPAP, as the benefit of CPAP in this subgroup is unclear.

If you have moderate OSA and are not sleepy (only snoring), ask your doctor if you can try tirzepatide alone. Since CPAP's benefit in asymptomatic moderate OSA is unclear, tirzepatide might resolve your OPA without the need for a machine. This requires monitoring and may not be suitable for everyone.

GLP-1 receptor agonists may have disease-modifying effects on osteoarthritis and osteoporosis by reducing inflammation and promoting bone formation.

If you have joint pain or weak bones, ask your doctor if your GLP-1 medication might offer extra protection. While weight loss is the main benefit, these drugs may also reduce inflammation in joints and help maintain bone density.

GLP-1 receptor agonists (GLP-1RAs) reduce the risk of hepatic decompensation events in patients with type 2 diabetes and compensated cirrhosis compared to DPP4 inhibitors and sulfonylureas.

If you have type 2 diabetes and compensated cirrhosis, GLP-1 receptor agonists may help reduce your risk of serious liver complications like fluid buildup or bleeding compared to other common diabetes medications. Discuss the benefits and risks with your doctor.

In obese or overweight individuals with low glucose effectiveness (Sg), subclinical reactive hypoglycemia (SRH) acts as a biological driver for frequent snacking, creating a vicious cycle that promotes obesity.

If you struggle to stop snacking despite gaining weight, it may not be a failure of willpower but a metabolic response. Specifically, if you have low glucose effectiveness, your body may drop into subclinical hypoglycemia after meals, triggering intense hunger to protect your brain. To break this cycle, focus on lifestyle factors that improve glucose effectiveness, such as regular walking (≥8000 steps/day) and reducing high-fat/sugar intake, rather than relying solely on willpower to resist snacks.

Menstrual cycle symptoms are widespread and severe in resistance-trained athletes, with 92% reporting symptoms and 76% reporting cramps, yet MC irregularities are not more common than in the general exercising population.

Expect menstrual symptoms like cramps and fatigue to be common (92% prevalence) regardless of your competitive level. However, do not assume your resistance training is causing irregular periods; your cycle regularity is likely similar to other women. Focus on managing the high prevalence of symptoms (like cramps and fatigue) through tracking and potentially hormonal or lifestyle interventions.

GLP-1 receptor agonists (GLP-1 RAs) reduce alcohol consumption and craving in patients with Alcohol Use Disorder (AUD) by modulating the mesolimbic dopamine reward pathway.

If you have AUD, especially if you also have obesity or Type 2 Diabetes, GLP-1 medications (like Semaglutide) may help reduce your alcohol intake and cravings by affecting brain reward pathways. This is an emerging off-label use, so discuss it with your doctor, particularly if standard treatments have failed or caused side effects.

GLP-1 agonists do not directly cause acne vulgaris; reported acne-like symptoms are likely injection-site hypersensitivity reactions or secondary to weight-loss-induced hormonal changes (e.g., IGF-1 increases).

If you are using a GLP-1 agonist and develop acne, it is likely not the drug directly attacking your skin. Instead, the weight loss you are experiencing may trigger hormonal shifts (like increased IGF-1) that worsen acne. Alternatively, any lumps you see are likely injection-site reactions, not acne. Consult your doctor to distinguish between these causes.

GLP-1 receptor agonists (GLP-1 RAs) reduce systemic and intestinal inflammation in Inflammatory Bowel Disease (IBD) by modulating immune cell signaling, enhancing the intestinal epithelial barrier, and improving gut microbiota composition.

If you have IBD and are considering GLP-1 medications (like Semaglutide or Liraglutide) for weight loss or diabetes, current evidence suggests they may actually help your gut health by reducing inflammation and lowering the risk of surgery. Start with a low dose and titrate slowly to manage nausea. Monitor your symptoms, but know that studies show these drugs do not increase the risk of IBD flares or hospitalizations compared to other diabetes medications. If you are underweight, discuss this carefully with your doctor, as the primary benefit in obese IBD patients is well-documented.

Long-term use of incretin agonists shows attenuated efficacy over time, with weight loss and HbA1c improvements diminishing significantly in the 3rd to 7th year of treatment.

If you are on incretin medication for several years, you may notice that the weight loss and blood sugar improvements slow down or plateau. This is a known biological response (tachyphylaxis). It does not mean the drug has stopped working entirely, but it may require dose adjustments or intensified lifestyle efforts to maintain benefits.